Peri Mets / MSS-CRC Immunotherapy Trial (Oncolytic Virus + anti-PDL1)
Posted: Sat Nov 19, 2016 9:07 am
PERITONEAL MET PATIENTS:
I know there has been a lot of interest in the oncolytic virus + PD(L)1 inhibitor strategy after I recently signed up for the NCT02636036 trial. I also wanted to post this because peri mets can be resistant to chemotherapy.
It is one experimental strategy to try to convert a cold MSS tumor into a highly inflamed tumor which "looks more like" a MSI-high CRC or HPV+ tumor in that regard (all of which often respond to PD(L)1 inhibitors).
This new Oncolytic virus + PDL1 inhibitor trial is opening in January. Trial sites so far: NYC and Buffalo, NY. It is specifically recruiting CRC patients with peritoneal mets.
Their inclusion criteria on paper looks a bit strict (can you join after failing FOLFIRI or do you need to at least try TAS/Stivarga first?) but you can see how strictly they interpret it by presenting your medical situation and seeing what they say.
https://clinicaltrials.gov/ct2/show/NCT02963831
Cheers,
-DK37
I know there has been a lot of interest in the oncolytic virus + PD(L)1 inhibitor strategy after I recently signed up for the NCT02636036 trial. I also wanted to post this because peri mets can be resistant to chemotherapy.
It is one experimental strategy to try to convert a cold MSS tumor into a highly inflamed tumor which "looks more like" a MSI-high CRC or HPV+ tumor in that regard (all of which often respond to PD(L)1 inhibitors).
This new Oncolytic virus + PDL1 inhibitor trial is opening in January. Trial sites so far: NYC and Buffalo, NY. It is specifically recruiting CRC patients with peritoneal mets.
Their inclusion criteria on paper looks a bit strict (can you join after failing FOLFIRI or do you need to at least try TAS/Stivarga first?) but you can see how strictly they interpret it by presenting your medical situation and seeing what they say.
https://clinicaltrials.gov/ct2/show/NCT02963831
Cheers,
-DK37